Author/Authors :
Motavallizadeh، نويسنده , , Somayeh and Fallah-Tafti، نويسنده , , Asal and Maleki، نويسنده , , Saeedeh and Shirazi، نويسنده , , Amir Nasrolahi and Pordeli، نويسنده , , Mahboobeh and Safavi، نويسنده , , Maliheh and Ardestani، نويسنده , , Sussan Kabudanian and Asd، نويسنده , , Shaaban and Tiwari، نويسنده , , Rakesh and Oh، نويسنده , , Donghoon and Shafiee، نويسنده , , Abbas and Foroumad، نويسنده ,
Abstract :
Several novel N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamide derivatives were prepared as potential antiproliferative agents. The in vitro antiproliferative activity of the synthesized compounds was investigated against a panel of tumor cell lines including breast cancer cell lines (MDA-MB-231, T-47D) and neuroblastoma cell line (SK-N-MC) using MTT colorimetric assay. Etoposide, a well-known anticancer drug, was used as a positive standard drug. Among synthesized compounds, 4-methoxy-N-(9-oxo-9H-xanthen-4-yl)benzenesulfonamide (5i) showed the highest antiproliferative activity against MDA-MB-231, T-47D, and SK-N-MC cells. Furthermore, pentafluoro derivatives 5a and 6a exhibited higher antiproliferative activity than doxorubicin against human leukemia cell line (CCRF-CEM) and breast adenocarcinoma (MDA-MB-468) cells. Structure–activity relationship studies revealed that xanthone benzenesulfonamide hybrid compounds can be used for the development of new lead anticancer agents.
Keywords :
Xanthone , Antiproliferative activity , CANCER , Benzenesulfonamides
